Table 2.
Decrease or delay in cancer treatment during COVID-19 pandemic.
| Study | Treatment | Patient No. | Anatomic site | Pre-COVUD | Post COVID | Reasons | Country |
|---|---|---|---|---|---|---|---|
| Morris et al. (44) | Surgery | 3381 | colorectal | 2003 | 1378 | reduced endoscopy | England |
| Xu et al. (50) | Surgery | 1538 | colorectal | 828 | 710 | older patients at risk for infection reduced endoscopy |
China |
| Li et al. (51) | Surgery | 8357 | breast | 7075 | 1282 | quarantine | China |
| Choi et al. (52) | Surgery | 2901 | colorectal | 1985 | 916 | unclear | Korea |
| Metzger et al. (53) | Surgery | 624 | colorectal | 180 | 121 | unclear | Germany |
| Okuyan et al. (54) | Surgery | 301 | colorectal | 180 | 121 | Delay of electivce Surgery, virus fear |
Turkey |
| Guerrieri et al. (55) | Surgery | 1248 | genitourinary | 720 | 528 | Delay of elective surgery |
Italy |
| Russel et al. (56) | Surgery | 3889 | all sites | 2336 | 1553 | Reduced surgical capacity | England |
| Karacin et al. (59) | Chemotherapy | 3661 | all sites | 11.6% postponed | 14.2% postponed | virus fear | Turkey |
| Sun et al. (60) | Chemotherapy | 62 | colon | unknown | 50% postponed | hospital policy | China |
| Beypinar et al. (61) | Chemotherapy | 159 | lung col0orectal | 3.7% postponed | 39.8& | hospital policy Virus fear |
Turkey |
| Valdiviezo et al. (62) | Chemotherapy | 1828 | all sites | unknown | 51.6% postponed 10.3% discontinued |
unclear | Peru |
| Chen et al. (63) | Chemotherapy | 117 | head and neck | unknown | 60.6% discontinued | Lockdown | China |
| Gabor et al. (64) | Chemotherapy | 146 | gynecologic | unknown | 24.6% modification | hospital policy patient cancellation |
USA |
| Prabhash et al. (65) | Chemotherapy | 514 | Lung, CNS, urologic head and neck |
unknown | 16% modification | unclear | India |
| Gatfield et al. (66) | Chemotherapy | 62 | breast | unknown | 16% discontinuation | Patient decision linked to old age | England |
| Xi et al. (67) | Radiotherapy | 209 | lung, breast, GI head and nech |
unknown | 53% discontinuation | lockdown | China |
| Lee et al. (68) | Radiotherapy | 566 | breast | 6.6% interruption | 8.2% interruption | COVID | Korea |
| Mitra et al. (69) | Radiotherapy | 94 | all sites | unknown | 88% delay | COVID-19 | India |
| Yu et al. (70) | Radiotherapy | 140 | all sites | unknown | 100% discontinuation | lockdown | China |
| Rakici et al. (71) | Radiotherapy | 195 | all sites | unknown | 4.6% discontinuation | COVID-19 | Turkey |
| Koffler et al. (72) | Radiotherapy | NS | NS | 8.1& disscontinuation | 11.3% discontinuation | unclear | USA |
COVID-19, coronavirus disease 19; no, number; NS, not specified.